Trial · NCT01923818
Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
NCT01923818, Phase 2, Phase 3, Unknown, Xijing Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events. Trials, record NCT01923818. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01923818
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
- NCT number
- NCT01923818
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 3,700 participants, estimated
- Lead sponsor
- Xijing Hospital
- Conditions
- Ischemic Stroke, TIA
- Interventions
- rivaroxaban, Aspirin, placebo
- First posted
- 2013-08-16
- Last updated
- 2013-08-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | percentage of patients with new stroke (ischemic or hemorrhage) | 90 days | |
| Secondary | Percentage of patients with new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death) | 30 days | |
| Secondary | mRS score changes (continuous) and dichotomized at percentage with score 0 to 2 versus 3 to 6 | 30 days and 90 days | |
| Secondary | Changes in NIHSS scores | 90 days | |
| Secondary | moderate to severe bleeding events | 90 days | |
| Secondary | Total mortality | 90 days | |
| Secondary | Adverse events/severe adverse events reported by the investigators | 90 days |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26458895 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01923818
GET https://conductscience.org/api/trials/v1/NCT01923818/registered